evaluate the pharmaceuticals company wegovy on glp-1 drugs for diabetes Novo's becomes first drug approved MASH Wegovy® GLP-1 Semaglutide Injections -

The second was a single-blind study that examined exenatide vs no additional treatment for 12 months in 45 participants, finding that at the 14-month follow-up, there was low-certainty evidence that suggests exenatide improves motor impairment as assessed by the MDS-UPDRS Part III off medication (mean difference, 4.50

Reddys (DRRD) has built a strong pipeline of GLP-1 generics, including Ozempic and Rybelsus

Archived from the original (PDF) on 6 March 2026

Retatrutide stands out because it is a triple agonist

For users this could segway into an expansion of the private market and for payers this could provide an affordable entry point for public reimbursement